Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,389 total articles
Dollar Tree is set to benefit from a renewed 'trade down' in consumer spending amid higher energy and living costs. Fundamentals show steady revenue growth, strong free cash flow and an attractive multi-price rollout that is boosting ticket averages. Valuation is reasonable for a high-return-on-equity retailer. I recommend a tactical long at $101.3…
Helios Technologies (HLIO) looks set to recover after a volatile 2024-2025 cycle. Revenue beats, rising free cash flow and controlled leverage provide a cleaner fundamental backdrop. Combine that with constructive technical momentum and a still-reasonable valuation and you get a defined trade with asymmetric upside over the next 45 trading days.
Global X Uranium ETF (URA) offers concentrated exposure to uranium miners and nuclear suppliers at $54.84. Momentum indicators are bullish, short interest has compressed, and uranium fundamentals (prices and policy) are supportive. Trade idea: buy URA at $54.00, stop $50.50, target $62.28 over a mid-term (45 trading days) horizon.
Energy Vault (NRGV) has moved from breakthrough demonstrations to real projects and asset-backed funding. Recent contract wins and a sizable capital stack for Asset Vault create a path toward positive EBITDA; the trade plan targets $5.50 with a $2.90 stop on a long-term (180 trading days) horizon.
Willis Lease Finance (WLFC) is upgraded to Strong Buy. Recent engine-focused lease growth, record 2025 revenue of $730M and robust free cash flow ($252M) create a favorable risk-reward despite leverage and governance headlines. Entry $210.15, target $270, stop $185 over a 180-trading-day horizon.
Dutch Bros (BROS) remains one of the fastest-growing drive-thru coffee chains in the U.S., with high average unit volumes, healthy shop-level margins and a sticky loyalty program. The stock has corrected from its highs and offers a mid-term trading opportunity while the business proves it can scale without eroding unit economics. Initiate a tactica…
Universal Health Services (UHS) is trading at roughly 8x reported earnings with an enterprise value/EBITDA near 6x and free cash flow of $825M. Balance sheet metrics are reasonable and recent M&A (Talkspace) expands higher-growth outpatient/virtual behavioral exposure. For traders willing to hold for the next 45 trading days, UHS offers a compellin…
Frontdoor's subscription-heavy home service plan business is showing accelerating top-line growth and expanding margins while converting into meaningful free cash flow. The market has treated FTDR like a cyclical name, but recent results and cash generation argue for re-rating. This trade idea targets a move back toward the 52-week high, with a cle…
BioAge’s oral NLRP3 inhibitor BGE-102 is positioned to deliver a binary proof-of-concept readout on cardiovascular (CV) inflammation in 2H26. The company is well-funded after a January offering, carries low debt, and has already demonstrated tolerability and biomarker activity in Phase 1. This trade idea lays out an entry at $17.00, a stop at $12.5…
IonQ jumped sharply after a DARPA contract and a photonic interconnect demo linked two commercial trapped-ion systems. The rally has technical momentum and heavy volume, creating a tactical swing opportunity. This trade idea lays out an entry, stop and target for a mid-term (45 trading days) play while flagging valuation, cash burn and execution ri…
Biohaven's clinical disappointment on troriluzole and a pipeline pivot make the next six months binary. With Phase 2 obesity data due in H2 2026 and other readouts on the docket, the stock has upside if data surprises, but clinical and commercial uncertainty plus elevated short interest argue for a neutral stance. We downgrade to Hold and lay out a…
SoFi is a U.S. fintech platform trading well under its 52-week high, with improving technicals, strong customer growth narratives and meaningful short interest. At a $17 limit entry the setup offers asymmetric upside to $26 while keeping downside defined. This is a trade for nimble, risk-aware traders willing to stomach headline volatility.
Exelixis is trading below recent highs despite robust profitability, strong free cash flow ($876M in most recent period), and a growing pipeline led by zanzalintinib. The balance sheet is clean, valuations are reasonable (PE ~15x), and technicals are constructive. We like a tactical long targeting a re-rating as clinical and commercial catalysts un…
Palantir (PLTR) is being oversold on headlines that Anthropic's ARR growth threatens its business. The selloff is disproportionate to fundamentals: 2025 revenue growth near 70%, healthy free cash flow, and a government-heavy contract profile that is difficult for model vendors to displace. I upgrade to a tactical long with a clear entry at $142.15,…
BYD remains the best-executed vertically integrated EV play outside Tesla. With the stock trading near its 20/50-day moving averages, momentum turning bullish, and short interest elevated, we see a high-probability asymmetric trade. Enter at $13.91, stop at $12.00, target $18.50 over a long-term holding period (46-180 trading days).
Travere is priced like a profitable specialty pharma but still carries heavy optionality from sparsentan (FILSPARI). With the market increasingly expecting a favorable regulatory outcome for Filspari and takeover chatter resurfacing, a confirmed approval or clear commercial readout could force a re-rating. This trade lays out a pragmatic entry at $…
Uber looks attractive here: a $151.9B enterprise value and 24.1x EV/EBITDA priced into a business that is reporting durable revenue growth, $9.1B of free cash flow and accelerating ride pricing. This trade plan targets near-term re-rating as gross margins and take-rates improve.
Niagen Bioscience's strategic shift toward telehealth-driven clinics and subscription care is the kind of operational pivot that can re-rate a small clinical-stage player if execution follows. The trade here is to buy a defined position around $3.25 with a $6.00 target and a $2.50 stop, trading the combination of improved unit economics and visible…
Williams Companies (WMB) combines stable, fee-based pipeline cash flow with a long dividend track record and visible free cash flow. At roughly $70.83 today, the stock trades below its 52-week high with an EV/EBITDA of 17.3 and market cap near $86.6B. We recommend a long trade for income-focused investors with a clearly defined stop and target on a…
QuantumScape is at a crossroads: production milestones and Volkswagen field tests could re-rate the stock, but the company still carries large losses, meaningful cash burn, and binary execution risk versus peers. This trade idea lays out a long-biased, risk-defined plan on QS with precise entry, stop and target, anchored to the relative risks versu…
MeiraGTx is a clinical-stage gene therapy company that has pushed revenue from near-zero to material levels while licensing its AAV ophthalmology program to Eli Lilly. The market cap is sub-$1B and the stock has broken out; this trade aims to capture a mid/long-term re-rating as clinical and commercial catalysts surface. Entry $11.20, stop $9.00, t…
Vera Bradley (VRA) trades cheaply on revenue multiples and book value after a rough 2025. Recent technical strength, a clear brand-revitalization plan and low debt make a near-term swing long reasonable. This trade idea gives an entry at $3.70, a stop at $3.20 and a target at $4.10 over a mid-term (45 trading days) horizon — a plan sized for a high…
Nvidia remains the AI leadership story, but at a $4.85T market cap, stretched multiples, and near-overbought technicals, a tactical trim is warranted. I outline a short-term trade to capture a mean-reversion move while keeping conviction in the long-term secular AI thesis. Entry: $197.19. Target: $170.00. Stop: $205.00. Horizon: short term (10 trad…
BioMarin's $4.8B purchase of Amicus plugs two revenue-generating therapies into a company already operating in attractive rare-disease niches. With market cap near $10.7B, positive free cash flow, and management guidance that the deal will be accretive within 12 months, the risk/reward favors a buy for investors willing to hold through integration …
BitMine Immersion (BMNR) has pivoted into an ETH-treasury and staking operator. With a newly launched staking platform, a material ETH reserve (reported near 4% of supply) and bullish technicals, the stock looks positioned for a mid-term re-rate. This trade idea lays out a concrete entry at $21.60, a $33 target and a $17 stop, explains the fundamen…
